Clinical Trials Logo

Post-PV MF clinical trials

View clinical trials related to Post-PV MF.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05280509 Recruiting - Myelofibrosis Clinical Trials

Study of TL-895 Combined With Ruxolitinib in JAKi Treatment-Naïve MF Subjects and Subjects With MF Who Have a Suboptimal Response to Ruxolitinib

Start date: June 9, 2022
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates TL-895, a potent, orally-available and highly selective irreversible tyrosine kinase inhibitor for the treatment of Myelofibrosis. Participants must have MF (PMF, Post PV MF, or Post ET MF) who are JAKi treatment-naïve or those who have a suboptimal response to ruxolitinib.

NCT ID: NCT04640532 Recruiting - Myelofibrosis Clinical Trials

KRT-232 in Combination With TL-895 for the Treatment of R/R MF and KRT-232 for the Treatment of JAKi Intolerant MF

Start date: November 17, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluates KRT-232 in Combination With TL-895 for the Treatment of Relapsed or Refractory Myelofibrosis and KRT-232 for the Treatment of JAK Inhibitor Intolerant Myelofibrosis.